Samsung Biologics reported consolidated revenue of KRW 1.2 trillion and operating profit of KRW 338.6 billion for the third quarter of fiscal year 2024. The company emphasized its commitment to providing high-quality solutions and expanding its global partnerships to enhance value for clients.
In Q3’24, Samsung Biologics achieved a 15% increase in revenue compared to the previous year, reaching KRW 1.2 trillion, with an operating profit of KRW 338.6 billion. The company attributed these results to the performance of its plants and the utilization of its newest Plant 4, along with Plants 1 through 3.
The company has strengthened partnerships with top pharmaceutical clients and exceeded a total contract volume of USD 15.4 billion. Samsung Biologics has also received over 335 regulatory approvals, showcasing its commitment to quality and compliance.
Looking ahead, the company raised its annual revenue growth guidance to 15-20% and continues to focus on strategic initiatives such as the construction of a dedicated ADC facility and Plant 5. Samsung Biologics aims to meet the demand for complex biopharmaceuticals with advanced development platforms like S-AfuCHO™, S-OptiCharge™, and S-HiCon™.
Samsung Biologics is dedicated to integrating sustainable practices and has joined initiatives to decarbonize supply chains and promote responsible business practices. The company aims to build resilient supply chains that contribute to a sustainable healthcare ecosystem.
About Samsung Biologics Co., Ltd.
Samsung Biologics is a fully integrated CDMO service provider offering development and manufacturing solutions for biopharmaceutical products. The company’s facilities are equipped to serve varying client needs, and it continues to expand its capabilities to meet growing demand. Samsung Biologics is committed to delivering products on time with operational excellence and expertise.
Contact: Claire Kim, Head of Global Marketing & Communications, [email protected]